Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 17/20 | 0.84 |
| ▸ | FGFR1 | P11362 | 16/20 | 0.84 |
| ▸ | KDR | P35968 | 16/20 | 0.84 |
| ▸ | EGFR | P00533 | 9/20 | 0.84 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.64 |
| ▸ | AKT2 | P31751 | 1/20 | 0.55 |
| ▸ | SRC | P12931 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4416887 | 1.00 | PDGFRB (0.84) | PDGFRBFGFR1KDREGFRZAP70 | |
| SCHEMBL4408863 | 0.92 | PDGFRB (1.00) | PDGFRBFGFR1KDREGFRZAP70 | |
| SCHEMBL4408865 | 0.92 | PDGFRB (1.00) | PDGFRBFGFR1KDREGFRZAP70 | |
| SCHEMBL4405755 | 0.89 | PDGFRB (1.00) | PDGFRBFGFR1KDREGFRZAP70 | |
| SCHEMBL4405759 | 0.89 | PDGFRB (1.00) | PDGFRBFGFR1KDREGFRZAP70 | |
| SCHEMBL6390254 | 0.88 | PDGFRB (1.00) | PDGFRBFGFR1KDREGFRSRC | |
| SCHEMBL6390261 | 0.88 | PDGFRB (1.00) | PDGFRBFGFR1KDREGFRSRC | |
| SCHEMBL4416055 | 0.85 | PDGFRB (1.00) | PDGFRBFGFR1KDREGFRZAP70 | |
| SCHEMBL4416058 | 0.85 | PDGFRB (1.00) | PDGFRBFGFR1KDREGFRZAP70 | |
| SCHEMBL4414235 | 0.85 | KDR (0.84) | PDGFRBFGFR1KDREGFRZAP70 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2020408-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | Sugen, Inc. (US) | 2009-02-04 | — | — | EP | disclosed |
| US-7119090-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-6878733-B1 | Formulations for pharmaceutical agents ionizable as free acids or free bases | SUGEN, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-20030105151-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. | 2003-06-05 | — | — | US | disclosed |
| US-6395734-B1 | ANTICANCER AGENTS | SUGEN, INC. | 2002-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105151-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | DMPK, PDPK1, PLK2 | PDGFRB 1086/4885FGFR1 930/4885KDR 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.